Ultra Small Batch Manufacture & R&D from Hosokawa Micron
Hosokawa Micron's new series of Picoline machines, developed for ultra small batch production of one to hundreds of grams of material, offers the widest wet and dry processing options for clinical trials or ultra small scale production available on the market. Meeting the demands of R&D departments, research institutes and those processing expensive materials and active pharmaceutical ingredients this unique equipment for size reduction, mixing, classifying and particle design is developed in miniature from existing and proven Hosokawa Micron technology.
The Picoline range comprises nine individual machines, which can all be fitted into the same compact operating housing. The range includes Picoplex based on the UPZ impact mill, Picozirk an impact classifier mill, Picosplit which is an ultrafine air classifier, Picojet based upon the well know AFG opposed jet mill with integral classifier for ultrafine grinding, Piconizer a spiral jet mill, based on the Alpine AS mill, Picocross a pin mill, Picoliq a wet agitated media mill , largely identical to the AHM mill, Picobond a high energy mixer largely identical to the Nobilta product line and Picomix a high performance batch mixer for dry powders. The flexibility of single housing and easily transposable machines is a major plus point.
Developed from established Hosokawa machines, transfer to volume production is straight forward, reliable and problem free enabling a swift route to market for new products under development. Suitable for bench top or housing in a fume cupboard or compact isolator the units are easy to clean and user friendly. Controlled by means of a touch panel with a microprocessor housed within the platform operating data, settings and system flowcharts etc can be displayed and transmitted to external printers, USB sticks or LMS systems.
A range of accessories for feeding, metering, for example, is also available.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance